Skip to main content
CNTA
NASDAQ Life Sciences

Centessa Pharmaceuticals 被礼来(Eli Lilly)收购以加强睡眠-觉醒障碍管线

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$27.58
Mkt Cap
$3.707B
52W Low
$9.6
52W High
$30.58
Market data snapshot near publication time

summarizeSummary

礼来(Eli Lilly)(LLY) 已宣布其意图收购 Centessa Pharmaceuticals (CNTA) 以推进其睡眠-觉醒障碍治疗管线。对于 Centessa 来说,这是一个高度重要的事件,因为收购通常会为目标公司的股东带来显著的溢价,代表着一个决定性的估值事件。对于礼来(Eli Lilly),这次收购战略性地扩大了其在一个关键治疗领域的管线。投资者现在将关注收购的具体条款,包括每股价格和关闭交易所需的任何监管批准。

在该公告发布时,CNTA的交易价格为$27.58,交易所为NASDAQ,所属行业为Life Sciences,市值约为$37.1亿。 52周交易区间为$9.60至$30.58。 这则新闻被评估为积极市场情绪,重要性评分为9/10。 来源:Dow Jones Newswires。


show_chartPrice Chart

Share this article

Copied!

feed CNTA - Latest Insights

CNTA
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
CNTA
Mar 31, 2026, 4:38 PM EDT
Filing Type: DEFA14A
Importance Score:
10
CNTA
Mar 31, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
10
CNTA
Mar 31, 2026, 8:18 AM EDT
Filing Type: DFAN14A
Importance Score:
10
CNTA
Mar 31, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
CNTA
Feb 13, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
CNTA
Jan 21, 2026, 4:58 PM EST
Filing Type: 144
Importance Score:
8
CNTA
Jan 06, 2026, 6:23 PM EST
Filing Type: 8-K/A
Importance Score:
7
CNTA
Jan 02, 2026, 4:45 PM EST
Filing Type: 144
Importance Score:
9